SCHEMBL102106

SCHEMBL102106

[CH2]CCC(C)CCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.52
OPRM1 P35372 1/20 0.44
LMNA P02545 2/20 0.42
SPHK1 Q9NYA1 1/20 0.41
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41
PRKCZ Q05513 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKD1 Q15139 1/20 0.41
DNM1 Q05193 2/20 0.40
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11289246 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201848 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL102916 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL101659 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL199151 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL102766 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL199182 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL5090198 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL99895 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201353 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201905-A Cationic lipid 武田药品工业株式会社 2024-06-14 CN disclosed
WO-2024042211-A1 A POLYETHER-BASED DISPERSANT WITH A LIGHT STABILIZING EFFECT BASF SE (DE) 2024-02-29 WO disclosed
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
WO-2024018761-A1 NEUTRAL LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
US-20240024252-A1 LIPID NANOPARTICLE NITTO DENKO CORPORATION (JP) 2024-01-25 US disclosed
WO-2023191050-A1 PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION 日東電工株式会社 2023-10-05 WO disclosed
WO-2023188830-A1 LIPID NANOPARTICLES 国立大学法人北海道大学 2023-10-05 WO disclosed
EP-4223314-A1 LIPID NANOPARTICLE National University Corporation Hokkaido University (JP) 2023-08-09 EP disclosed
CN-116367718-A Lipid nanoparticles 国立大学法人北海道大学 2023-06-30 CN disclosed
WO-2023085299-A1 CATIONIC LIPID 武田薬品工業株式会社 2023-05-19 WO disclosed
EP-0425566-B1 NEW PHOTOSENSITIZING AGENTS HEALTH RESEARCH INC (US) 1994-10-12 EP disclosed
EP-0425566-A4 NEW PHOTOSENSITIZING AGENTS 1992-03-11 EP disclosed
US-5093349-A Porphyrins HEALTH RESEARCH INC. (US) 1992-03-03 US disclosed
EP-0206037-B1 CARBAMATES AND UREAS OF N-(2-AMINOACYLAMIDO-2-DESOXY-HEXOSYL) AMIDE, METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE BAYER AG (DE) 1992-01-15 EP disclosed
EP-0425566-A1 NEW PHOTOSENSITIZING AGENTS. HEALTH RESEARCH INC (US) 1991-05-08 EP disclosed
US-5002962-A Porphyrins HEALTH RESEARCH, INC. (US) 1991-03-26 US disclosed
WO-1990000895-A1 NEW PHOTOSENSITIZING AGENTS HEALTH RESEARCH, INC. (US) 1990-02-08 WO disclosed
US-4855283-A IMMUNE SYSTEM STIMULANTS BAYER AKTIENGESELLSCHAFT (DE) 1989-08-08 US disclosed
CN-86104185-A The preparation technology and the medicinal use thereof of N-(2-aminoacyl amino-2-deoxidation-hexose-based)-amides, amino formate and a ureas 1987-04-08 CN disclosed
EP-0206037-A2 Carbamates and ureas of N-(2-aminoacylamido-2-desoxy-hexosyl) amide, method for their preparation and their pharmaceutical use BAYER AG (DE) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024252-A1 LIPID NANOPARTICLE LIPC, ACOX1, ABCB4 ACE2 2922/4885OPRM1 1547/4885LMNA 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.